About US
Contact us
>>Back
NovoStent Gets CE Mark For Samba Stent, Delivery System
- Publisher：
- Publication：2010/3/4
NovoStent has received CE Mark for its Samba stent and delivery system for the treatment of peripheral artery disease. The Samba stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a combination of strength, flexibility and vessel coverage.
NovoStent said that CE Mark approval was supported by data from its Samba trial which enrolled patients in Germany in 2009.
NovoStent claimed that the Samba stent provides over 50% vessel coverage, more than twice that of slotted tube stents offered by medical device companies as Johnson & Johnson (JNJ), Abbott Laboratories (ABT), Boston Scientific (BSX) and Medtronic (MDT). NovoStent's stent and integrated delivery system is designed to provide easy deployment and accurate delivery.
Ray Martin, president and CEO of NovoStent, said: “We are extremely pleased with this approval and our ability now to offer a product that can treat just about any disease presentation in the SFA and popliteal artery.
"Our Samba Stent is creating an entirely new product category that combines the best attributes of stent-grafts and conventional stents. With over 50% metal coverage, the Samba Stent has the ability to hold back more disease than a conventional stent. But unlike a stent-graft, patency of side branch arteries can be maintained.”
Source: web of PBR